Dose response relationship of medical cannabis and symptom control in patients with pancreatic cancer: an analysis of the CANPAN trial.
Arjun Gupta, Kendall Lin, Ella Chrenka et al.
✦ AI-curated · Sources linked
In 30 seconds
This analysis of the CANPAN pilot waitlist-control randomized trial examined cannabis use, patient-reported outcome completion, and THC dose-response among 32 cannabis-naïve patients with newly diagnosed locally advanced or metastatic pancreatic adenocarcinoma. During assigned 8-week periods, 23 participants (72%) used cannabis, while outcome data were available for half the participants at 16 weeks. Higher average daily THC dose was associated with improvement in anxiety and insomnia; a dose of ≥ 10 mg daily was associated with mean improvement in 4 symptoms, compared with 2.1 symptoms at <10 mg.
Key findings
- At 16 weeks, patient-reported outcome data were available for 16 (50%) participants.
- Higher average daily THC dose was associated with improvement in anxiety (r = 0.52, P = .038) and insomnia (r = 0.53, P = .033).
- A ≥ 10 mg daily THC dose (vs <10 mg) was associated with mean improvement in 4 vs 2.1 symptoms.
Why it matters
The findings suggest that THC dose may relate to psychological symptom improvement and broader symptom control in patients with pancreatic cancer. This dose-response signal may help inform the design of future trials, while the limited availability of longer-term patient-reported data underscores the need to address outcome completion when evaluating sustained effects.
What to keep in mind
Patient-reported outcome data were available for only 50% of participants at 16 weeks, limiting assessment of longer-term outcomes. The dose-response analysis comes from a small pilot trial.